公司資料
Erasca 股價、新聞與催化劑
- 股票代碼:
- ERAS
- 交易所:
- NASDAQ
- 產業:
- Biopharma
- 所在地:
- United States
股票表現
17.63 USD (+3.22%)
收盤價
最後更新: 2026年8月21日
4.19B USD
市值
股價為何變動
The latest monitored company update is “Erasca Granted FDA Fast Track Designation for Pan-RAS Molecular Glue ERAS-0015 in Patients with Metastatic Pancreatic Adenocarcinoma.” The corresponding closing-price reaction is not yet available.
公司概覽
RAS/MAPK Precision Oncology
Erasca is a clinical-stage precision-oncology company developing therapies for cancers driven by the RAS/MAPK pathway. Its portfolio is designed to address genetically defined tumors through direct RAS inhibition.
ERAS-0015
ERAS-0015 is a pan-RAS molecular glue being evaluated in the AURORAS clinical program. Development includes monotherapy and combination strategies in KRAS-mutated pancreatic, lung, and colorectal cancers.
Registration-Oriented Development
Erasca plans potentially registration-enabling studies of ERAS-0015 in pancreatic and non-small cell lung cancers. The strategy spans later-line monotherapy and frontline combinations.
ERAS-4001
ERAS-4001 is a pan-KRAS inhibitor in the Phase 1 BOREALIS-1 study. The program is intended to broaden treatment coverage across KRAS-driven tumors beyond individual mutation subtypes.
未來催化劑
- Preliminary Phase 1 monotherapy data for ERAS-4001 in the second half of 2026.
- ERAS-0015 Phase 1 monotherapy expansion and combination dose-escalation data in the first half of 2027.
- Initiation of a potentially registration-enabling ERAS-0015 study in second-line or later NSCLC in the first half of 2027.
- Initiation of a Phase 3 ERAS-0015 study in first-line pancreatic ductal adenocarcinoma in 2027.
- Initiation of ERAS-4001 monotherapy expansion and combination dose-escalation cohorts in 2027.
- Initiation of a Phase 3 ERAS-0015 study in RAS-mutated NSCLC between the second half of 2027 and the first half of 2028.
近期新聞
- 01
- 02
- 03
- 04
- 05
相似股票
商業成熟度、治療領域或催化劑模式相近的同業公司。